Spyre Therapeutics Inc
SYREHealthcare|Biotechnology|USA
$97.74
-1.01 (-1.02%)
Tangible Book
$6.53
Ownership Breakdown
—
Institutional
—
Insider
—
Float
—
Shares Outstanding
Insider Trades (51)
| Insider | Position | Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Turtle Cameron | CEO | 2026-07-01 | SELL | 15,000 | $87.69 | $1315.4K |
| Burrows Scott L | CFO | 2026-07-01 | SELL | 7,500 | $87.74 | $658.1K |
| Sloan Sheldon | Chief Medical Officer | 2026-07-01 | SELL | 8,334 | $87.7 | $730.9K |
| Burrows Scott L | CFO | 2026-06-25 | SELL | 15,000 | $87.13 | $1307K |
| Fairmount Healthcare Fund II L.P. | Director | 2026-06-23 | SELL | 4,684,781 | $85.31 | $399658.7K |
| HENDERSON MICHAEL THOMAS | Director | 2026-06-22 | SELL | 20,000 | $100 | $2000K |
| Sloan Sheldon | Chief Medical Officer | 2026-06-03 | SELL | 8,333 | $75 | $625K |
| Burrows Scott L | CFO | 2026-06-01 | SELL | 7,500 | $71.06 | $533K |
| Turtle Cameron | CEO | 2026-06-01 | SELL | 15,000 | $70.43 | $1056.5K |
| HENDERSON MICHAEL THOMAS | Director | 2026-05-08 | SELL | 80,000 | $74.4 | $5952K |
| Burrows Scott L | CFO | 2026-05-01 | SELL | 12,500 | $71.37 | $892.1K |
| Sloan Sheldon | Chief Medical Officer | 2026-05-01 | SELL | 78,333 | $71.5 | $5600.8K |
| Turtle Cameron | CEO | 2026-05-01 | SELL | 15,000 | $71.37 | $1070.6K |
| Sloan Sheldon | Chief Medical Officer | 2026-04-01 | SELL | 7,958 | $50 | $397.9K |
| Burrows Scott L | CFO | 2026-04-01 | SELL | 7,500 | $49.34 | $370.1K |
| Turtle Cameron | CEO | 2026-04-01 | SELL | 15,000 | $49.33 | $740K |
| Burrows Scott L | CFO | 2026-03-03 | SELL | 2,500 | $40.65 | $101.6K |
| Turtle Cameron | CEO | 2026-03-02 | SELL | 15,000 | $42.19 | $632.9K |
| Turtle Cameron | CEO | 2026-02-02 | SELL | 15,000 | $32.8 | $492K |
| Turtle Cameron | CEO | 2026-01-02 | SELL | 15,000 | $30.68 | $460.2K |
| Turtle Cameron | CEO | 2025-11-03 | SELL | 45,000 | $23.33 | $1049.9K |
| Burrows Scott L | CFO | 2025-09-02 | SELL | 18,428 | $16.26 | $299.6K |
| Albers Jeffrey W. | Director | 2024-11-06 | SELL | 6,700 | $36.76 | $246.3K |
| Albers Jeffrey W. | Director | 2024-10-25 | SELL | 300 | $36.43 | $10.9K |
| Burrows Scott L | CFO | 2024-09-03 | SELL | 18,531 | $28.17 | $522K |
| Souza Marcio | Director | 2022-08-25 | BUY | 3,600 | $14 | $50.4K |
| Hanley Jr. Michael Conick | Chief Commercial Officer | 2022-06-08 | BUY | 1,128 | $17.75 | $20K |
| Quinn Anthony G. | President & CEO | 2022-03-16 | BUY | 3,203 | $58.5 | $187.4K |
| Quinn Anthony G. | President & CEO | 2022-03-15 | BUY | 5,787 | $48.5 | $280.7K |
| Alspaugh Jonathan | CFO | 2022-03-11 | BUY | 3,000 | $52 | $156K |
| Shanafelt Armen | Director | 2021-12-13 | BUY | 6,000 | $91.5 | $549K |
| Quinn Anthony G. | President & CEO | 2021-12-10 | BUY | 2,145 | $92.75 | $199K |
| Alspaugh Jonathan | CFO | 2021-12-09 | BUY | 2,000 | $93 | $186K |
| Alspaugh Jonathan | CFO | 2021-08-18 | BUY | 1,615 | $162.75 | $262.8K |
| Quinn Anthony G. | President & CEO | 2020-04-30 | BUY | 6,600 | $118.75 | $783.8K |
| Quinn Anthony G. | President & CEO | 2019-06-14 | BUY | 1,276 | $154 | $196.5K |
| Quinn Anthony G. | President & CEO | 2019-05-22 | BUY | 1,064 | $169.25 | $180K |
| Quinn Anthony G. | President & CEO | 2019-05-17 | BUY | 749 | $168.75 | $126.3K |
| Schuchart Aaron | Chief Business Officer | 2018-09-27 | SELL | 240 | $237.5 | $57K |
| Quinn Anthony G. | President & CEO | 2018-08-15 | BUY | 120 | $176.25 | $21.1K |
| Novartis Bioventures Ltd | 10% Owner | 2018-05-11 | SELL | 782 | $251.5 | $196.7K |
| Novartis Bioventures Ltd | 10% Owner | 2018-05-10 | SELL | 2,958 | $253 | $748.4K |
| Novartis Bioventures Ltd | 10% Owner | 2018-05-08 | SELL | 1,684 | $251.5 | $423.6K |
| Quinn Anthony G. | Interim CEO | 2017-12-08 | BUY | 332 | $124 | $41.1K |
| York Charles N II | CFO and VP | 2017-12-05 | BUY | 1,038 | $112 | $116.3K |
| Quinn Anthony G. | Director | 2017-12-05 | BUY | 685 | $121.5 | $83.2K |
| ORBIMED ADVISORS LLC | 10% Owner | 2017-02-21 | BUY | 4,372 | $129 | $564K |
| LILLY ELI & CO | 10% Owner | 2016-04-12 | BUY | 20,000 | $250 | $5000K |
| Quinn Anthony | Director | 2016-04-12 | BUY | 400 | $250 | $100K |
| Novartis Bioventures Ltd | 10% Owner | 2016-04-12 | BUY | 12,000 | $250 | $3000K |
| Cox Russell J. | Director | 2016-04-12 | BUY | 280 | $250 | $70K |
Congress & Senate Trades
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Guru Activity
1 gurus tracked